GlassScriptPhysician profile
Brian C Center
NPI 1790908796
$3,367.20
in general payments reported to CMS, 2019-2025
45 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $80.93 · 2021: $80.65 · 2022: $222 · 2023: $503 · 2024: $438 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $367.06 | 2022-2025 | |
| Novocure INC. | $245.20 | 2020-2025 | Optune Gio, Optune Lua (Novottf-200t), Optune |
| Novartis Pharmaceuticals Corporation | $231.71 | 2022-2025 | |
| Janssen Biotech, INC. | $216.83 | 2024-2025 | Erleada, Balversa, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $209.46 | 2024-2025 | Libtayo |
| Siemens Medical Solutions USA, INC. | $171.22 | 2023 | |
| Merck Sharp & Dohme LLC | $166.15 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $152.39 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| Boston Scientific Corporation | $142.39 | 2023 | Spaceoar System |
| Incyte Corporation | $132.56 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Beone Medicines USA, INC. | $101.65 | 2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $90.89 | 2025 | Orserdu, Elzonris |
| Genentech USA, INC. | $73.31 | 2025 | Polivy, Itovebi, Phesgo |
| Takeda Pharmaceuticals U.S.A., INC. | $72.72 | 2025 | Ninlaro, Fruzaqla, Iclusig |
| Pharmaessentia USA Corporation | $69.97 | 2025 | Besremi |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Center listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.